Harrow, Inc. (HROW) Analyse boursière

Présentation de l'entreprise

Harrow, Inc. operates as an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products within the United States market. The enterprise functions through two distinct segments, namely Branded and ImprimisRx, with the latter offering ImprimisRx, an ophthalmology-focused compounded medication. This organization is situated within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a specialization in niche therapeutic areas and generic formulations rather than broad-market blockbuster drugs. In terms of scale, the company holds a market capitalization of $1.37B and generates annual revenue of $272.30M while employing a workforce of 373 individuals. These valuation and revenue figures indicate that Harrow, Inc. occupies a mid-cap position in the specialty drug landscape, possessing sufficient revenue volume to support R&D activities yet maintaining a relatively lean operational footprint compared to large-cap pharmaceutical peers.

Santé financière

The company reports a trailing twelve-month revenue of $272.30M and an EBITDA of $48.82M, while simultaneously recording a net income loss of $-5,139,000. The significant gap between the positive EBITDA and the negative net income reveals a substantial cost structure burden, likely driven by non-operating expenses, interest obligations, or one-time charges that erode bottom-line profitability despite operational cash generation. Despite the net loss, Harrow, Inc. generates positive free cash flow of $45.18M, which signifies strong financial flexibility allowing the firm to fund operations, repay debt, or invest in new product pipelines without requiring external equity dilution. The company maintains a robust liquidity position with $75.06M in cash on hand against a total debt load of $251.98M, although the high debt-to-equity ratio of 483.72 suggests a leveraged balance sheet where equity capital is minimal relative to obligations. Short-term liquidity appears secure given a current ratio of 2.20, indicating that the firm holds more than double the current assets required to cover its current liabilities. Return on equity stands at -8.5% and return on assets is 4.8%; these divergent metrics reveal that while asset utilization generates a positive return, the negative equity base distorts ROE, reflecting the company's phase of growth or restructuring where earnings are yet to fully capitalize the shareholder equity.

Évaluation de la valorisation

Valuation multiples for Harrow, Inc. show a forward P/E of 13.50 against a trailing P/E that is listed as N/A, a discrepancy that implies the market prices the stock based on future projected earnings rather than historical profitability, likely due to the current net loss status. The price-to-book ratio is recorded at 26.07, indicating that the market values the company at a significant premium over its net asset value, suggesting high growth expectations or intangible asset valuation. Alternative valuation metrics include a price-to-sales ratio of 5.02 and an EV/EBITDA of 31.63, which suggest the company is valued highly relative to its sales and operational earnings, typical for biotech and specialty pharmaceutical firms in development or early commercialization phases. Regarding trading range, the stock has a 52-week high of $54.85 and a 52-week low of $20.85, placing the current market price within a wide volatility band that reflects significant investor sentiment shifts over the past year. The beta value of 0.31 indicates that the stock exhibits low volatility relative to the broader market, moving less than one-third as much as the market index, which offers a distinct risk profile for portfolios seeking lower correlation assets.

Growth & Income

Harrow, Inc. demonstrates a revenue growth rate of 33.3% year-over-year contrasted with an earnings growth rate of -10.3%, indicating that top-line expansion is occurring while profitability remains under pressure, a common dynamic during market expansion where revenue gains have not yet translated into net income. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available earnings and cash flow back into the business for research and development rather than distributing income to shareholders. This reinvestment strategy aligns with the company's growth profile, prioritizing long-term product pipeline development over current income generation for investors. The overall growth and income profile presents a high-revenue expansion trajectory with zero current income distribution, suitable for investors seeking capital appreciation in the specialty pharmaceutical sector who are comfortable with negative earnings and no dividend yield.